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Background:  Additional  ablation  of  complex  fractionated  atrial electrograms  (CFAE)  after  pulmonary  vein
isolation  (PVI)  has  been  shown  to  improve  the  success  of  ablation  of  persistent  atrial  ﬁbrillation  (AF).
However,  extensive  ablation  is  often  necessary  to  eliminate  all CFAE  or  to  terminate  AF.  We  assessed  the
usefulness  of  the  administration  of  an  antiarrhythmic  drug  (AAD)  before  CFAE  ablation.
Methods  and  results:  One-hundred  and  ten  patients  with  persistent  AF  ﬁrst  underwent  PVI,  roof  and
ﬂoor  linear  ablation  (box  isolation).  One  hundred  patients  who  remained  in AF  after  box isolation  were
then randomized  to either  receive  (AAD  group,  n = 50)  or  not  receive  (no-AAD  group,  n  = 50)  intravenous
nifekalant  (0.3  mg/kg)  followed  by  a  CFAE  ablation.  In the  AAD  group,  nifekalant  terminated  AF  in  19
(38%)  patients  and  ablation  of  localized  CFAE  was  performed  in 31  patients  who  remained  in AF after
nifekalant,  and  terminated  AF  in 11  (35%)  patients.  In  the  no-AAD  group,  ablation  of CFAE  terminated  AF
in  13  (26%)  patients.  The  AAD  group  had  a signiﬁcantly  lesser  number  of radio  frequency  applications  at
CFAE  sites  (18  ± 12  versus  36 ± 10,  p <  0.0001)  and  shorter  procedure  time  (162  ± 34 versus  197 ± 29  min,
p  <  0.0001)  compared  with  the  no-AAD  group.  However,  there  was  no signiﬁcant  difference  in  success
rate  at  12  months  after  a single  ablation  procedure  between  the  two  groups  (AAD  group,  74% versus
no-AAD  group,  76%).
Conclusions:  An approach  to  ablation  using  nifekalant  may  be useful  in  localizing  areas  of CFAE,  reduc-
ing  the  number  of  applications  at CFAE  sites  and  procedure  time.  Ablation  of  only  CFAE  localized  with
nifekalant  may  be sufﬁcient  for  clinical  outcome.
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Pulmonary vein (PV) isolation is effective for treating paroxys-
al  atrial ﬁbrillation (AF) [1,2], however, not enough for cure of
ersistent AF [3].  To improve the clinical outcome in patients with
ersistent AF, extensive ablation, including multiple linear lesions
nd/or ablation of complex fractionated atrial electrograms (CFAE),
as been adopted [4–11]. CFAE are sometimes recorded over dif-
use areas and numerous ablation applications are often necessary
o eliminate all CFAE or to terminate AF. Although the most robust
ndpoint may  be termination of AF, this generally requires a very
ong procedure time [7].  Furthermore, extensive ablation is associ-
ted with procedural complications, proarrhythmia [6], and stroke
isk, and may  compromise atrial mechanical function [12]. An opti-
al  strategy may  identify sites of CFAE targeted with ablation and
esult in AF termination with an acceptable clinical outcome. It is
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possible that the administration of an antiarrhythmic drug (AAD)
may  help accomplish this. However, AAD might eliminate not only
bystander CFAE but also culprit CFAE, and it is unclear whether
ablation of only CFAE localized with AAD is sufﬁcient for a desirable
outcome. Therefore, we assessed the usefulness of the administra-
tion of AAD before performing CFAE ablation.
Methods
The trial was  designed as a prospective, randomized, nonblinded
study. All patients referred to the Fukuoka Sanno Hospital for abla-
tion of AF were screened. Exclusion criteria included paroxysmal AF
or atrial ﬂutter. Eligible patients were randomized in a 1:1 fashion
after PV isolation, roof and ﬂoor linear ablation (i.e. box isolation) to
either the AAD or no-AAD group. The patients who showed termi-
nation of AF during or just after box isolation were excluded before
randomization.Patient characteristics
The study population consisted of 110 consecutive patients
with persistent (n = 47) and longstanding persistent AF (n = 63) who
vier Ltd. All rights reserved.
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Table  1
Baseline characteristics.
Characteristic AAD group (n = 50) No-AAD group (n = 50)
Age (years) 56 ± 10 57 ± 11
Male sex (%) 88 90
Pers. AF/long AF 19/31 18/32
AF duration (month) 31 ± 34 30 ± 32
LA  diameter (mm) 46 ± 6 45 ± 4
LA  volume (ml) 73 ± 18 71 ± 20
LV  ejection fraction (%) 60 ± 7 61 ± 7
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TAD, antiarrhythmic drug; Pers. AF/long AF, persistent/longstanding persistent
trial ﬁbrillation; LA, left atrial; LV, left ventricular.
ere referred for catheter ablation guided by NavX system (NavX,
ith CFE Software, St. Jude Medical, Minnetonka, MN,  USA). Per-
istent AF was deﬁned as AF that was sustained for more than
 days but which required pharmacologic or electrical cardiover-
ion. Longstanding persistent AF was deﬁned as continuous AF
hat had lasted for more than one year. A mean of 2 ± 1 anti-
rrhythmic drugs had been administered, but failed to maintain
 normal sinus rhythm. None of the patients had been treated
ith amiodarone within the 6 months preceding the procedure. No
tructural heart disease was present in 43 patients. Hypertension
as present in 52 patients and coronary artery disease was  docu-
ented in 7. Ten patients who showed AF termination during or
ust after box isolation were excluded before randomization. One
undred patients who remained in AF after box isolation were then
andomly assigned to receive (AAD group, n = 50) or not receive (no-
AD group, n = 50) intravenous nifekalant (0.3 mg/kg). There were
o signiﬁcant differences in the patient characteristics or substrate
roperties between the two groups (Table 1).
lectrophysiological study
Written informed consent was obtained from all patients. The
atients received oral anticoagulants for at least 2 months before
blation. Transoesophageal echocardiography was  performed to
xclude any left atrial (LA) thrombi before ablation. Antiarrhyth-
ic  drugs were discontinued ﬁve half-lives before ablation. A 5-Fr
uadripolar electrode catheter (St. Jude Medical) was placed in
he right atrial appendage, and a 6-Fr octopolar electrode catheter
Japan Lifeline, Tokyo, Japan) was placed in the coronary sinus.
riple transseptal punctures were performed, and three 8-Fr SL0
heaths (St. Jude Medical) were advanced into the LA. During the
rocedure, heparinization was continued to maintain an activated
lotting time of 300–400 s. The surface electrocardiograms (ECG)
nd bipolar endocardial electrograms were continuously moni-
ored and stored on a computer-based digital ampliﬁer/recorder
ystem for ofﬂine analysis (LabSystemTM PRO, Bard Electrophysiol-
gy, Lowell, MA,  USA). The intracardiac electrograms were ﬁltered
rom 30 to 500 Hz and measured at a sweep rate of 200 mm/s. Atrial
acing was performed using a programmed stimulator (SEC-3102,
ihon Kohden, Tokyo, Japan).
Two decapolar ring catheters (Lasso, Biosense-Webster, Dia-
ond Bar, CA, USA) were inserted into the LA and used for the
apping of PVs. A deﬂectable, 7-Fr ablation catheter (Cool path
uo, St. Jude Medical) was also inserted into the LA for mapping
nd ablation. A 3D geometry of the LA was created using the NavX
ystem.
ox isolationAblation was performed during AF with an irrigated-tip 4-mm
blation catheter (Cool path duo, St. Jude Medical).
Radio frequency energy was delivered at a power of 30–40 W.
he temperature was limited to 40 ◦C. The luminal oesophageal Cardiology 61 (2013) 44–48 45
temperature was  monitored with a catheter in the oesophagus
close to the tip of the ablation catheter. During ablation at the
posterior LA close to the oesophagus, ablation was  performed at
a maximum power of 20 W and a temperature of 40 ◦C. If the
oesophageal temperature was  higher than 40 ◦C, radio frequency
applications were interrupted. Radio frequency energy was deliv-
ered for 30 s at each point.
Continuous lesions at the anterior portions of the ipsilateral
superior and inferior PVs were initially created under guidance
of a Lasso catheter and the NavX system. Ablation was started at
the superior wall and continued around the anterior and inferior
venous perimeter. At the posterior portions of the PVs, ablation was
sequentially targeted to antral segments with the earliest activity
until PV isolation was  achieved.
Ablation of the LA roof was then performed by creating a con-
tiguous line of ablation lesions to join the superior PVs. Finally,
ablation of the LA ﬂoor was  performed by creating a contiguous
line of ablation lesions that joined the inferior PVs to isolate the
posterior LA. The entrance block of a box lesion during AF was  con-
ﬁrmed by the elimination of PV potentials and posterior LA using a
circular mapping catheter.
Mapping of CFAE
After box isolation, CFAE mapping was  performed using a 4-
mm-tip ablation catheter during AF by point-to-point contact
mapping. Regarding the mapping sites for analysis, these were
nearly equally distributed in the LA, and the sampling sites were
collected from each of the subanatomical regions of the LA except
the box region, i.e. the anterior LA, septal LA, anterior roof, inferior
LA, lateral LA, around the mitral annulus, and the LA appendage
region. In each region, at least 20 points were determined. The
points in each region were similar in number and were nearly
equally distributed. The NavX mapping parameters were set to
“CFE-mean”, which is an interval-analysis algorithm that produces
a colour map  that is representative of the CFAE distribution. The
CFAEs were characterized by cycle-length values obtained from
each site using a recording duration of 6 s. This duration was  deter-
mined based on Lin’s [13] report that the assessment of fractionated
electrograms required a recording duration of ≥5 s at each site to
obtain a consistent fractionation. The parameters of the automatic
algorithm for CFAEs have been described previously. According to
the criteria proposed by Nademanee et al. [5],  CFAEs were deﬁned
as fractionated electrograms composed of two or more deﬂections
with a mean cycle length ≤ 120 ms.  Non-CFAEs were deﬁned as
having a mean cycle length of >120 ms.
Ablation of CFAE
In the no-AAD group, after complete CFAE mapping, ablation of
CFAE was  then performed. In the AAD group, nifekalant (0.3 mg/kg)
was administered for over 5 min. After nifekalant, the CFAE map
was created again in the patients who  remained in AF. The mean
AF cycle length at the coronary sinus, the maximal CFAE (shortest
cycle length), the mean degree of CFAE, and the proportion of CFAEs
in the LA (% of LA with a mean cycle length <120 ms)  were compared
before and after drug administration. After re-mapping, ablation of
CFAE localized by nifekalant was then performed. In both groups,
the endpoint of CFAE ablation was  the elimination of all identiﬁ-
able target electrograms or termination of AF. If AF converted to
atrial tachycardia or ﬂutter during ablation, mapping and ablation
were performed to terminate the atrial tachycardia or ﬂutter. If the
patient remained in AF despite the elimination of all visible CFAE,
electrical cardioversion was performed to restore sinus rhythm.
During sinus rhythm, exit block of the box lesion was conﬁrmed.
Gaps along the ablation lines were detected and closed using high
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Table 2
Substrate properties before and after nifekalant.
Substrate factors Before drug After drug p-Value
Mean AFCL (ms) 147 ± 12 209 ± 22 <0.0001
Maximal CFAE (shortest CL) (ms) 50 ± 7 58 ± 8 <0.0001
Mean CFAE (mean CL) (ms) 73 ± 7 87 ± 10 <0.0001
Proportion of CFAE (%) 54 ± 11 32 ± 14 <0.0001
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Table 3
Comparison of procedural data between 2 approaches.
Parameters AAD group (n = 31) No-AAD group
(n = 50)
p-Value
No. of RF at CFAE 18 ± 12 36 ± 10 <0.0001
RF  time (min) 65 ± 16 87 ± 11 <0.0001
Procedure time (min) 162 ± 34 197 ± 29 <0.0001
Fluoroscopy time (min) 35 ± 10 46 ± 12 <0.001
Nademanee et al. [9] used intravenous ibutilide to highlightFCL, atrial ﬁbrillation cycle length; CFAE, complex fractionated atrial electrograms.
oltage (10 V) pace mapping through the ablation catheter. With
ack of LA capture, the line was considered as complete at this loca-
ion. In case of LA capture, a gap was suspected and radio frequency
nergy was delivered simultaneously while pacing from the tip of
he ablation catheter. The endpoint of box isolation was  deﬁned as
idirectional conduction block, that is both lack of potentials in box
nd lack of LA capture. AF induction was not performed.
ost-ablation care and follow-up
Intravenous heparin was administered to all patients for 24 h
fter the procedure, followed by warfarin for 3 months. After the
blation, all AADs were prescribed for 2 months to prevent the early
ecurrence of AF. Surface ECG, transthoracic echocardiography and
4-h Holter recording were performed the day after the procedure,
nd repeated at 1, 3, 6 and 12 months. All patients were provided
ith a telemetry ECG recorder (Omron HCG-801, Kyoto, Japan)
or 1 month at 6 months after ablation to document symptomatic
pisodes or to record an ECG once per week if asymptomatic. AF
ecurrence was deﬁned as an episode that lasted more than 1 min
nd that was conﬁrmed by ECGs 2 months after ablation (blanking
eriod).
tatistical analysis
All of the statistical analyses were performed using the SAS (Sta-
istical Analysis System) Software Package (Ver. 9.2, SAS Institute
nc., Cary, NC, USA). Categorical variables were compared between
roups by a 2 analysis with a Fisher’s exact test. Continuous vari-
bles were compared between groups by the Student’s t-test or
ilcoxon rank-sum test. Data are presented as the mean ± SD.
hanges in the substrate properties before and after drug adminis-
ration were examined by the Wilcoxon signed-rank test. Statistical
igniﬁcance was set at a p-value less than 0.05.
esults
ffects of nifekalant on AF
In the AAD group, after box isolation, nifekalant terminated AF
n 19 patients (AF converted to sinus rhythm in 14, perimitral ﬂut-
er in 3, and typical ﬂutter in 2). In these patients, re-mapping of
FAE and additional ablation of CFAE could not be performed, and
herefore, these patients were excluded from subsequent analysis
f the effects of nifekalant on CFAE characteristics.
In 31 patients who remained in AF after nifekalant, the LA
ubstrate characteristics were assessed before and after the admin-
stration of nifekalant. As shown in Table 2, nifekalant signiﬁcantly
rolonged the mean AF cycle lengths, the maximal CFAE (shortest
ycle length), mean degree of CFAE and signiﬁcantly reduced the
roportion of CFAE. The spatial distribution of CFAE in the LA also
iffered after nifekalant (Fig. 1).AAD, antiarrhythmic drug; RF, radio frequency; CFAE, complex fractionated atrial
electrograms.
Ablation of CFAE
In the AAD group, ablation of localized CFAE was  performed in
31 patients who remained in AF after nifekalant, and terminated AF
in 11 (35%) patients (AF converted to sinus rhythm in 7, focal atrial
tachycardia in 3 and perimitral ﬂutter in 1).
In the no-AAD group, ablation of CFAE terminated AF in 13 (26%)
patients (AF converted to sinus rhythm in 7, typical ﬂutter in 3,
perimitral ﬂutter in 2 and focal atrial tachycardia in 1).
Comparison of procedural data between two approaches
Table 3 shows a comparison of the procedural data between
the two groups. The AAD group had a signiﬁcantly lesser number
of radio frequency applications at CFAE sites, shorter total radio
frequency time, procedure and ﬂuoroscopy time compared with
the no-AAD group.
Success rate
At 12 months after a single ablation procedure, 37 patients (74%)
in the AAD group and 38 patients (76%) in the no-AAD group were
free of AF without AAD. There was  no signiﬁcant difference in suc-
cess rate after a single ablation procedure between the two groups.
Patients without AF recurrence had a signiﬁcantly smaller LA
diameter (46 ± 6 mm versus 50 ± 4 mm,  p < 0.02) and LA volume
(74 ± 20 ml  versus 89 ± 17 ml,  p < 0.05) compared with patients
with AF recurrence. Patients with AF termination had a signiﬁ-
cantly higher rate of change in AF cycle length (51 ± 27% versus
32 ± 17%, p < 0.01) and mean CFAE (25 ± 6% versus 17 ± 5%, p < 0.01),
and lower recurrence rate (10% versus 45%, p < 0.01) than those
without AF termination.
Discussion
Box isolation and CFAE ablation
We  have provided an approach for complete isolation of the
posterior LA including all PVs, i.e. box isolation [14]. In our pre-
vious study, with box isolation alone, 60% of the patients with
persistent or longstanding persistent AF were arrhythmia-free after
a single procedure without AAD [15]. In the present study, with
a hybrid approach of box isolation plus CFAE ablation, 75% of
the patients with persistent or longstanding persistent AF were
arrhythmia-free after a single procedure without AAD. Thus, addi-
tional ablation of CFAE outside the box area may  improve the
clinical outcome in the patients with persistent or longstanding
persistent AF.
Effects of AAD on CFAECFAE associated with perpetuating AF after CFAE ablation, if
the patient remained in AF despite the elimination of all visi-
ble CFAE. They demonstrated that the ablation of CFAE resulted
K. Kumagai, H. Toyama / Journal of Cardiology 61 (2013) 44–48 47
Fig. 1. Regional distribution of complex fractionated atrial electrograms (CFAE) in the left atrium (LA) before and after nifekalant and the corresponding bipolar electrograms
during  atrial ﬁbrillation (AF). CFAE mapping revealed multiple CFAE sites (white colour), including the LA septum, LA anterior wall and LA appendage (LAA) base region.
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ength;  RSPV, right superior pulmonary vein; RIPV, right inferior pulmonary vein.
n the termination of AF in 95% of the patients, however, 28%
equired concomitant ibutilide treatment [9].  In contrast, we  used
ifekalant before performing CFAE ablation. Nifekalant is a com-
aratively pure IKr channel blocker [16]. Nifekalant reduced areas
f CFAE by prolonging the AF cycle length, probably due to the
odiﬁcation of refractoriness. Nifekalant may  block ﬁbrillatory
onduction from focal drivers and eliminate some CFAE. We  previ-
usly evaluated the effects of nifekalant on the electrophysiological
roperties of PV and LA in patients with AF [17]. Nifekalant mainly
rolonged the effective refractory period of LA rather than PV.
herefore, after box isolation, nifekalant may  have an effect on
trial tissue outside the box. Na+ channels are down-regulated
y electrical remodeling in persistent AF, whereas K+ channels
re not disturbed [18]. This may  help to explain why nifekalant
as an effect on AF termination in persistent or longstanding
ersistent AF.
Although AAD might eliminate not only bystander CFAE but
lso culprit CFAE, the AAD group could achieve a success rate as
igh as that of CFAE ablation without AAD. This suggests that most
FAE that are eliminated by AAD may  be bystander CFAE, while
AD-resistant CFAE may  be culprit for AF perpetuation. Therefore,
blation of only CFAEs localized with AAD may  be sufﬁcient for
linical efﬁcacy.
linical implications
The endpoints of CFAE ablation are either the termination of
F or the elimination of all CFAE. However, this often requires a
ery long procedure and extensive CFAE ablation is associated with
rocedural complications. Lin et al. [19] demonstrated that PV iso-
ation eliminated some CFAE, and therefore complete PV isolation
hould be performed before CFAE ablation to avoid unnecessary
ubstrate modiﬁcation. However, in longstanding persistent AF, a
ong procedure is often needed to achieve the endpoints of CFAE
blation even after PV isolation. An approach to CFAE ablation
sing nifekalant can facilitate AF termination despite minimizing
he ablation lesions, thereby reduce the number of radio frequency
pplications required and procedure time with an acceptable suc-
ess rate.owed CFAE. Ablation of the CFAE localized with nifekalant terminated AF. CL, cycle
Limitations
First, the density of the mapping sites may not have been high
enough.
Second, the results of this study are in part based on the effect of
nifekalant and the ablation of CFAE after box isolation. Therefore,
the cumulative effects may  have led to the termination of AF.
Third, recurrence of AF may  not only be associated with CFAE,
but also other factors including reconnection through a gap after
box isolation and non-PV foci in addition to CFAE.
Conclusions
An approach to ablation using nifekalant may be useful in
localizing areas of CFAE targeted with ablation, resulting in AF
termination and reducing procedure time. Ablation of only CFAE
localized with nifekalant may  be sufﬁcient for clinical efﬁcacy in
patients with persistent or longstanding persistent AF.
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